After one CAR-T infusion, three of six RA patients stop their drugs

Paradox: a cancer therapy turns down joint inflammation

For a decade, six people with severe rheumatoid arthritis cycled through therapy after therapy. Biologics, targeted drugs, immunosuppression — nothing held the disease. Pain, swelling, and limited motion stayed. Then they received a single infusion of a cell therapy built first for blood cancers. Months later, three of them were no longer taking any rheumatoid arthritis medicine.

This is not a magic pill from a pharmacy. It is the phase 1 result of the COMPARE trial at Charité in Berlin, reported in Nature Medicine (DOI: 10.1038/s41591-026-04603-3). The product is called mivocabtagene autoleucel, or miv-cel: the patient’s own T cells fitted with a receptor that hunts the CD19 protein on B cells.

Why rheumatoid arthritis can become a dead end

Rheumatoid arthritis is an autoimmune disease. The immune system attacks the joints. Inflammation returns in waves, damages cartilage and bone, and quality of life falls. Modern drugs often hold inflammation in check, but they rarely “reset” the disease. Patients stay on treatment for years. For some people even newer biologics are not enough. Clinicians then speak of treatment-refractory rheumatoid arthritis.

One hypothesis points to memory B cells — cells that, after an infection, hide in lymph nodes, bone marrow, or joint tissue itself. They produce antibodies against the body’s own proteins and reignite inflammation. Standard drugs do not always reach those hidden reservoirs. Hence the idea from David Simon’s and Gerhard Krönke’s team: aim at them with the same weapon that, in oncology, clears B cells in blood cancers.

What they did in phase 1

The nonrandomized phase 1 enrolled six people: three women and three men, roughly ages 31 to 69. All had severe, seropositive rheumatoid arthritis — with ACPA antibodies — and a history of as many as eight prior targeted or biologic therapies without lasting control.

Before the infusion they stopped all disease-modifying antirheumatic drugs. Patients went through standard lymphodepletion, a short preparatory chemotherapy that makes room for the new cells. Then a single miv-cel infusion. Follow-up lasted 36 to 52 weeks.

Primary endpoints covered safety in the first four weeks: cytokine release syndrome (CRS), ICANS neurotoxicity, and other adverse events. Secondary and exploratory endpoints looked at clinical efficacy and at what happens to cells and antibodies.

Safety: a signal, not absolute calm

CRS occurred in all six. Importantly: only grades 1 and 2 — mild to moderate, manageable. There was no ICANS. There were no serious adverse events. One dose-limiting toxicity was recorded: grade 3 transaminase elevation that resolved without sequelae.

That was enough to call the primary endpoint met and move to phase 2. It does not mean the therapy is “safe forever.” It means that in this small group the short horizon looked acceptable for a cell therapy.

What happened to the disease

CAR T cells cleared CD19-marked B cells in blood and tissues — including bone marrow, lymph nodes, and the joint. In parallel, autoantibodies fell. Four of six people seroconverted for ACPA against mutated citrullinated vimentin. Five of six lost rheumatoid factor IgM.

Even though nobody returned to immunosuppression, disease activity fell in everyone. The median DAS28-CRP reduction at the latest follow-up was 34 percent. DAS28-CRP remission and an ACR70 response — a 70 percent improvement by American College of Rheumatology criteria — appeared in three of six patients.

Charité’s public note adds the clinical picture: three people needed no rheumatoid arthritis drugs during the observation window. When the B-cell system rebuilt, mainly naïve cells returned, not those “trained” to attack self tissue. At the same time, vaccine antibodies — including against chickenpox and tetanus — could still be detected. The reset did not look like a total wipe of protective memory.

The fact boundary is sharp here. Some patients had incomplete responses. In one person the disease returned after a medicine-free stretch. Six people are a signal, not a population proof. Nobody has a rheumatoid arthritis marketing authorization yet.

The oncology paradox in rheumatology

CAR T was built to kill malignant B cells. Here the same mechanism — a receptor seeking CD19 — is meant to clear diseased, auto-aggressive B cells and give the immune system a fresh start. That paradox has been circulating in autoimmunity for several years: a weapon from hematology arrives on the rheumatology ward.

In oncology, CD19 CAR T is already a product. In rheumatoid arthritis it is still an experiment. The difference matters for a business reader. We are not buying a ready “joint” therapy off the shelf today. We are buying a thesis: if a B-cell memory reset also works outside cancer, a new indication class opens for cell platforms already being built in Europe and the US.

An earlier TRL09 piece on CAR T (#96) focused mainly on manufacturing and time from collection to drip. Today the protagonist is the indication: severe, treatment-refractory, seropositive rheumatoid arthritis. Same technology family, different clinical stake.

Phase 2 and the product path

The next COMPARE stage is to add about ten patients and compare CAR T with an already approved rheumatoid arthritis drug that also targets B cells. The question is whether a one-time infusion gives a stronger or more durable effect than continuous B-cell therapy.

We put this story at TRL 4–5. First-in-human phase 1 is done, short-term safety allowed progress, but a larger cohort, longer follow-up, and a head-to-head versus standard of care are still missing. Autologous T-cell manufacturing, lymphodepletion, and CRS care are mature pieces from hemato-oncology — the novelty is the autoimmune indication and the thesis of resetting pathogenic memory.

For cell companies the stake is expanding the CD19 platform beyond cancer. For payers — whether a one-time, expensive infusion can, in selected cases, replace years of biologics. For patients with refractory rheumatoid arthritis — whether an option to “zero out” appears instead of another immunosuppression line.

The trial is registered as NCT06475495. Kyverna Therapeutics provided logistical support; according to Charité the company did not design the protocol or analyze the data. That matters for reading conflicts of interest: the clinical signal comes from an academic center, not a marketing brochure.

What this means for Europe and Poland

Berlin shows that European transplant and rheumatology centers can run first-in-human autoimmune cell therapy. In Poland, CAR T in hemato-oncology is already entering practice in selected centers. The rheumatoid arthritis question is clinically premature for now — and strategically live: who will build the pathway for eligibility, manufacturing, and non-cancer care if phase 2 and later trials confirm the signal.

For a Polish reader the stake is not “a drip in the clinic tomorrow.” It is rather: severe, multi-drug-refractory rheumatoid arthritis may gain a new therapy class, and European university hospitals are lining up at the start. If a B-cell reset works, it changes not only a patient’s prognosis but also the business model: less chronic drug, more one-time intervention with a high unit price and a high eligibility bar.

What CD19 actually does

CD19 is a protein on many B cells — both malignant ones and those that sustain autoaggression in rheumatoid arthritis. The patient’s T cells are collected from blood, receive an artificial receptor (CAR) that recognizes CD19 in the lab, and return to the body in one infusion. Inside they seek cells with that “name tag” and destroy them. For a time the whole CD19-positive population disappears, including the one hidden in the joint.

This is not a weekly tablet. It is a one-time cell intervention with preparatory lymphodepletion and a CRS risk known from hemato-oncology. That is why phase 1 had to answer the safety question first, and only then the remission question.

Numbers worth remembering

Six people. CRS grades 1–2 in all. Zero ICANS. One transient grade 3 liver toxicity. Median 34 percent DAS28-CRP drop. DAS28-CRP remission plus ACR70 in three of six. ACPA (vimentin) seroconversion in four, RF IgM in five. Follow-up up to a year. Trial ID: NCT06475495.

Those numbers will not replace phase 2. They do give investors and clinicians a shared language: the signal is measurable, not anecdotal, and it comes from a journal that does not publish corridor curiosities.

How to read the result without the hype

Six people. CRS in everyone, though mild. One grade 3 liver toxicity. Three remissions with ACR70 and no drugs in the observation window. Falling autoantibodies. Preserved vaccine antibodies. That is a strong phase 1 signal — and a list of reasons not to announce a breakthrough on breakfast television.

The paradox remains. A therapy designed against cancer quiets joints because it targets the same CD19 “identifier” on B cells. Until phase 2 shows an advantage over an existing B-cell drug, we stay with a careful verdict: worth going further, worth building manufacturing and clinical capacity, not worth promising an “arthritis drug” already.

For TRL09 this is exactly the interesting moment. Not a finished product on the shelf, but the moment an oncology platform opens the door to a new disease class — with numbers you can check in a DOI, and a fact boundary written in plain sight.